Review
Published on 16 Nov 2022
Impact of SOX2 function and regulation on therapy resistance in bladder cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1020675
- 2,186 views
- 5 citations
Type at least 3 characters
1,766 articles
Articles
Original Research
Published on 16 Nov 2022
Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1033035
- 2,454 views
- 7 citations
Review
Published on 15 Nov 2022
Ferroptosis in osteosarcoma: A promising future
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1031779
- 3,580 views
- 21 citations
Original Research
Published on 15 Nov 2022
Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1057455
- 2,391 views
- 6 citations
Review
Published on 14 Nov 2022
The role of noncoding RNAs in cancer lipid metabolism
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1026257
- 2,072 views
- 5 citations
Original Research
Published on 10 Nov 2022
Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.993243
- 2,030 views
- 6 citations
Brief Research Report
Published on 10 Nov 2022
Laparoscopic electrochemotherapy for the treatment of hepatocellular carcinoma: Technological advancement
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.996269
- 1,555 views
- 6 citations
Case Report
Published on 09 Nov 2022
Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1009076
- 2,073 views
- 3 citations
Review
Published on 07 Nov 2022
TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1034842
- 4,063 views
- 22 citations
Original Research
Published on 03 Nov 2022
Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1012236
- 2,180 views
- 1 citation
Original Research
Published on 03 Nov 2022
GZ17-6.02 kills prostate cancer cells in vitro and in vivo
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1045459
- 2,172 views
- 5 citations
Case Report
Published on 31 Oct 2022
ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1010084
- 1,639 views
- 4 citations
Systematic Review
Published on 31 Oct 2022
HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1030825
- 1,403 views
- 2 citations
Original Research
Published on 31 Oct 2022
WFDC21P promotes triple-negative breast cancer proliferation and migration through WFDC21P/miR-628/SMAD3 axis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1032850
- 2,366 views
- 5 citations
Case Report
Published on 31 Oct 2022
Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1006017
- 2,731 views
- 4 citations
Original Research
Published on 27 Oct 2022
Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.934076
- 6,125 views
- 7 citations